Ahmed Ahmed, Abdel-Aziz Tarek A, AlAsaad Mohannad M R, Majthoob Motaz
Department of Cardiothoracic Surgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Department of Cardiothoracic Surgery, Dubai Hospital, Dubai, United Arab Emirates.
J Card Surg. 2021 Apr;36(4):1492-1498. doi: 10.1111/jocs.15350. Epub 2021 Jan 21.
Mitral valve repair (MVr) is the gold standard for the treatment of degenerative mitral valve regurgitation (MR). The recently introduced NeoChord DS1000 has gained increasing recognition as a feasible, potentially safe, and effective procedure with minor complications and promising outcomes. This study aims to conduct a systematic review of the published literature that discusses the technical feasibility and outcome of transapical off-pump MVr with NeoChord DS1000 device implantation in the treatment of degenerative MR.
This review was performed according to the PRISMA statement. Databases searched in this review included Pubmed, Web of Science, Scopus, and Cochrane databases for systematic reviews. All English articles on humans reporting isolated MVr using NeoChord DS1000 device were included provided that basic preoperative data, operative specifications, and postoperative mortality and morbidity were reported.
This review included six studies comprised 249 patients who had NeoChord mitral procedure. Almost all patients included had severe MR (243/249, 97.6%). Operative success was achieved in 241 out of the 249 patients (96.8%). No intraoperative mortality was reported. Intraoperative arrhythmia was reported in six patients (2.4%) and significant bleeding was reported in eight patients (3.2%).
Awaiting more evidence, NeoChord mitral procedure appears to be a promising procedure that can be considered in selected cases.
二尖瓣修复术（MVr）是治疗退行性二尖瓣反流（MR）的金标准。最近推出的NeoChord DS1000作为一种可行、潜在安全且有效的手术方法，并发症少且预后良好，越来越受到认可。本研究旨在对已发表的文献进行系统综述，这些文献讨论了经心尖非体外循环MVr联合NeoChord DS1000装置植入治疗退行性MR的技术可行性和结果。
本综述按照PRISMA声明进行。本综述检索的数据库包括用于系统评价的Pubmed、科学网、Scopus和Cochrane数据库。纳入所有报道使用NeoChord DS1000装置进行孤立性MVr的英文人体研究，前提是报告了基本术前数据、手术规范以及术后死亡率和发病率。
本综述纳入了6项研究，共249例接受NeoChord二尖瓣手术的患者。几乎所有纳入患者都有严重MR（243/249，97.6%）。249例患者中有241例手术成功（96.8%）。未报告术中死亡。6例患者（2.4%）报告有术中心律失常，8例患者（3.2%）报告有严重出血。
在等待更多证据的情况下，NeoChord二尖瓣手术似乎是一种有前景的手术方法，可在特定病例中考虑。
